Aryl-fused imidazole TRPV1 inhibitor, preparation method therefor and use thereof
By designing novel aryl imidazole compounds to selectively block capsaicin activation of the TRPV1 channel, the problem of elevated body temperature caused by existing TRPV1 antagonists has been solved, achieving highly effective treatment of pain and epilepsy while reducing drug side effects.
Patent Information
- Application Number
- PCT/CN2026/094812
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-06
- Filing Date
- 2026-05-06
- Publication Date
- 2026-11-12
AI Technical Summary
Existing TRPV1 antagonists often cause fever when blocking pain signal transmission, and existing antiepileptic drugs have significant side effects, making it difficult to meet clinical needs.
A novel aryl imidazole compound was developed to selectively block capsaicin activation of the TRPV1 channel without affecting acid activation through specific structural design. The compound was prepared in a pharmaceutically acceptable salt form for the preparation of TRPV1 channel inhibitors.
The compound exhibits significant TRPV1 antagonistic activity, effectively treating a variety of pain and epilepsy conditions without causing an increase in body temperature. It also demonstrates high bioavailability and safety, providing a wider safety window.
Smart Images

Figure PCTCN2026094812-FTAPPB-I100001 
Figure PCTCN2026094812-FTAPPB-I100002 
Figure PCTCN2026094812-FTAPPB-I100003
Abstract
Description
An aryl imidazole TRPV1 inhibitor, its preparation method and uses
[0001] Cross-referencing
[0002] This application is based on and claims priority to CN application No. 202510573403.3, filed on May 6, 2025, the disclosure of which is incorporated herein by reference in its entirety. Technical Field
[0003] This disclosure pertains to the pharmaceutical field, specifically relating to a novel class of TRPV1 channel inhibitors, their preparation methods, pharmaceutically acceptable salts, and pharmaceutical compositions comprising them, as well as the use of the aforementioned compounds, salts, or compositions in the preparation of medicaments for treating diseases related to TRPV1 activity. These diseases include painful conditions such as chronic pain, neuropathic pain (traumatic, diabetic, metabolic, infectious, toxic, anticancer treatment-induced, or iatrogenic), arthritic pain, rheumatic pain, fibromyalgia, back pain, cancer-related pain, facial neuralgia, headache, migraine, toothache, burn pain, postherpetic neuralgia, muscle pain, central or peripheral nerve compression pain, spinal cord or brain trauma pain, spinal cord or brain ischemic pain, neurodegenerative pain, pain following a spinal cord or brain hemorrhage, post-stroke pain; and seizures or epilepsy, chronic cough, asthma or airway hyperresponsiveness, atopic dermatitis, or psoriasis-related pruritus. Background Technology
[0004] TRPV1 (Transient Receptor Potential Vanillic Isotype 1) is a non-selective cation channel first cloned and identified in 1999 by David Julius' team at the University of California (Nature. 1999; 398(6726): 436-41.). It is characterized by its wide distribution and complex biological functions, making it an important target in drug development. It is mainly distributed in sensory neurons of the peripheral nervous system, such as small-to-medium diameter C fibers and some Aδ fibers in the dorsal root ganglion (DRG), trigeminal ganglion (TG), and vagus ganglion. In addition, its expression can also be seen in some non-neural tissues, such as keratinocytes, mast cells, and bladder epithelium.
[0005] This channel can be directly activated by a variety of noxious stimuli, including high temperatures (>42°C), low pH (<6.5), endogenous lipid molecules (such as arachidonic acid ethanolamine), and exogenous agonists (such as capsaicin). Upon activation, TRPV1 mediates Ca2+... 2+ and Na +Influx of these signals induces neuronal depolarization, thereby initiating and transmitting pain, heat, and itch signals. It also participates in regulating neurogenic inflammation, the cough reflex, and visceral sensitivity. Based on these mechanisms, TRPV1 channels are widely involved in various pathological processes, including pain (inflammatory pain, neuropathic pain, visceral pain, cancer pain, and postherpetic neuralgia), chronic cough, asthma or airway hyperresponsiveness, gastroesophageal reflux chest pain, overactive bladder / interstitial cystitis, atopic dermatitis / psoriasis-related pruritus and neurogenic inflammation, and arthritic pain. Therefore, TRPV1 channels have become an important therapeutic target for these diseases.
[0006] Drug discovery targeting TRPV1 has largely focused on preclinical and clinical research related to pain and atopic dermatitis. Currently, a number of novel TRPV1 antagonists and agonists have been reported, with the potential to change the current clinical reliance on opioid analgesia. At present, the only FDA-approved TRPV1-targeting drug is a topical formulation of capsaicin—high-concentration capsaicin (such as...). The patch, which induces TRPV1 desensitization and damage to nociceptor function, provides analgesia. However, this therapy often causes severe pain upon initial application, is limited to local administration, and has limited indications, severely restricting its widespread use (Proc Natl Acad Sci US A. 2016; 113(2):E137-45). TRPV1 antagonists inhibit Ca2+ by blocking channel opening. 2+ / Na + The influx of pain receptors and the release of pain neuropeptides (such as substance P and CGRP) block pain signal transmission. Theoretically, their side effect spectrum should be superior to that of opioids and NSAIDs. However, most TRPV1 antagonists (such as AMG517) have failed in clinical trials because they completely block all activation modes of TRPV1 (capsaicin, acid, heat), interfering with thermoregulation and inducing hyperthermia. This has become the main bottleneck for their translation (Pain. 2008; 136(1-2):202-10). To date, no related drugs have been successfully marketed.
[0007] The discovery of TRPV1 antagonists that can significantly relieve pain without causing fever remains a key research focus. Studies have shown that some antagonists can selectively block specific activation modes of TRPV1 channels. For example, some compounds inhibit capsaicin activation without affecting acid activation (J Neurosci. 2010; 30(4):1435-40). This selectivity for activation modes leads to differentiated in vivo effects. A typical example is AMG-8562, which completely blocks capsaicin activation while preserving acid-activated TRPV1 channel currents; in animal models, AMG-8562 effectively relieves pain without causing fever (J Med Chem. 2014; 57(17):7412-24). This discovery points the way to developing a new generation of TRPV1 antagonists that avoid the side effect of fever.
[0008] Based on the current state of research, it is still necessary to develop highly active TRPV1 antagonists that do not cause an increase in body temperature.
[0009] Furthermore, epilepsy is a clinical syndrome caused by recurrent abnormal electrical discharges in brain nerve cells, leading to brain dysfunction. It typically begins in childhood and persists throughout life. Currently, there are approximately 50 million people with epilepsy worldwide, and about 10 million in my country, with approximately 400,000 new cases each year. Epilepsy has become the second most common neurological disease after headaches, causing immense suffering for patients and their families, and placing a significant burden on society. Except for a very small percentage of epilepsy patients who require brain surgery or neuromodulation therapy, medication is the primary treatment for epilepsy. However, currently available antiepileptic drugs can only control seizures in about 70% of patients. Besides commonly causing sedation and drowsiness, they can also produce irreversible side effects on the nervous system, such as cerebellar dysfunction, extrapyramidal dysfunction, and peripheral neuropathy.
[0010] Therefore, it is of great significance to further design and develop novel antiepileptic active compounds with definite antiepileptic efficacy. Summary of the Invention
[0011] The technical problem solved by this disclosure is to provide a novel compound or a pharmaceutically acceptable salt thereof having TRPV1 inhibitory activity and not causing an increase in body temperature, a pharmaceutical composition comprising said compound, and the use of said compound in the preparation of a medicament for treating diseases related to TRPV1 activity.
[0012] To solve the above-mentioned technical problems, this disclosure provides the following technical solutions:
[0013] In one aspect, the compounds described in this disclosure have the structure of the following general formula A:
[0014] in
[0015] X is a nitrogen atom or -CH-;
[0016] Y is One of them, in which the nitrogen atom is bonded to Z;
[0017] Z is either -CH2- or -C(=O)-
[0018] R1, R2, and R3 are each independently selected from H, halogen atoms, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups, cyano groups, trifluoromethyl groups, and nitro groups.
[0019] The compounds described in this disclosure, or their pharmaceutically acceptable salts, wherein the compounds are selected from the following:
[0020] Pharmaceutically acceptable salts of the compounds described in this disclosure may be salts formed by the compounds and acids selected from at least one of maleic acid, succinic acid, citric acid, tartaric acid, fumaric acid, formic acid, acetic acid, propionic acid, malonic acid, oxalic acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, hydrobromic acid, hydroiodic acid, sulfuric acid, taurine, malic acid, lactic acid, and gluconic acid.
[0021] The second aspect of this disclosure provides a method for preparing the said compound or a pharmaceutically acceptable salt thereof, comprising the following steps.
[0022] Step a: o-aryldiamine 1 reacts with compound 2 under the action of a condensing agent to generate compound 3;
[0023] Step b: Compound 3 is deprotected by the Boc protecting group to obtain compound 4 or its salt.
[0024] Step c: Compound 4 or its salt reacts with an aryl aldehyde under the action of a base and a reducing agent to produce the compound shown in formula A;
[0025] Step d: Compound 4 or its salt reacts with an arylic acid in the presence of a base, an activator, and a condensing agent to produce the compound shown in formula A;
[0026] In step a, the condensing agent is selected from one of CDI, DCC, and EDCI; the reaction solvent is selected from one of DMF and DMAC; and the reaction temperature is 100℃-170℃; wherein, CDI, DMF, and 150℃ are preferred reaction conditions.
[0027] In step b, the Boc protecting group is removed by one of the following reactions: hydrochloric acid, hydrogen chloride / ethyl acetate solution, and trifluoroacetic acid. The hydrogen chloride / ethyl acetate solution is preferred for the removal of the protecting group.
[0028] In step c, the reaction solvent for the reductive amination reaction is a haloalkane, preferably dichloromethane; the base is one or more of trimethylamine, triethylamine, DIPEA, and DBU, preferably triethylamine; the reducing agent for the reductive amination reaction is selected from one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride, preferably sodium triacetoxyborohydride; the reaction temperature is 0℃-25℃, preferably 25℃.
[0029] In step d, the base for the amidation reaction is selected from triethylamine or pyridine, with triethylamine being preferred; the amide condensing agent is selected from dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC), or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), with EDCI being preferred; the condensation activator is selected from 4-N,N-dimethylpyridine (DMAP) or 1-hydroxybenzotriazole (HOBt), with HOBt being preferred; and the reaction temperature for the amidation reaction is 0℃-25℃, with 25℃ being preferred.
[0030] A third aspect of this disclosure provides a class of pharmaceutical compositions comprising, as an active ingredient, a compound described in this disclosure or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
[0031] The fourth aspect of this disclosure provides the use of the said compound or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition thereof, in the preparation of a TRPV1 channel inhibitor.
[0032] The fifth aspect of this disclosure provides the use of the said compound or a pharmaceutically acceptable salt thereof, or the said pharmaceutical composition, in the preparation of a medicament for the prevention or treatment of diseases related to TRPV1 activity.
[0033] Furthermore, the diseases associated with TRPV1 activity include: pain disorders, chronic cough, asthma or airway hyperresponsiveness, or dermatitis-related pruritus.
[0034] Furthermore, the pain conditions include: chronic pain, neuropathic pain, arthritic pain, rheumatic pain, fibromyalgia, back pain, cancer-related pain, facial neuralgia, headache, migraine, toothache, burn pain, postherpetic neuralgia, muscle pain, central or peripheral nerve compression pain, spinal cord or brain trauma pain, spinal cord or brain ischemic pain, neurodegenerative pain, pain following a spinal cord or brain hemorrhage cerebrovascular accident, or pain following shock.
[0035] Furthermore, the neuropathic pain includes traumatic pain, diabetic pain, metabolic pain, infectious pain, toxic pain, pain induced by anticancer treatment, or iatrogenic neuropathic pain.
[0036] Furthermore, this disclosure also provides the use of the said compound or a pharmaceutically acceptable salt thereof, or the said pharmaceutical composition, in the preparation of a medicament for the prevention or treatment of seizures or epilepsy.
[0037] This disclosure also involves the following:
[0038] 1. A (N-substituted-2-piperidinyl)-imidazopyridine derivative, characterized in that the compound and its pharmaceutically acceptable salt have structures shown in Formulas I, II, and III (corresponding to compounds T-29, T-66, and T-34 of the embodiments of this disclosure, respectively):
[0039] 2. A pharmaceutical composition comprising the compound described in claim 1 as the active ingredient, and further comprising one or more pharmaceutical carriers or one or more known pharmaceutical diluents.
[0040] 3. Use of the compound described in item 1 or the pharmaceutical composition described in item 2 in a drug for the treatment or prevention of seizures or epilepsy.
[0041] 4. A method for preparing the compound described in claim 1, characterized in that it comprises the following steps:
[0042] (1) Compound 1 undergoes a reduction amination reaction with 3-fluorobenzaldehyde and 3,5-bis(trifluoromethylbenzaldehyde) under the action of alkali and reducing agent to produce compounds shown in formula I and II;
[0043] (2) Compound 1 reacts with 2,4-dichloro-5-fluorobenzoic acid under the action of a base, an activator and a condensing agent to generate the compound shown in Formula III;
[0044] 5. In the preparation method described in item 4, in step (1), the base is one or more of trimethylamine, triethylamine, DIPEA, and DBU, and the reducing agent for the reduction amination reaction is selected from one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride. The reaction temperature for the reduction amination reaction is 0℃-25℃.
[0045] 6. In the preparation method described in item 4, in step (2), the base for the amidation reaction is selected from triethylamine or pyridine, the amide condensing agent is selected from one of dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), the condensation activator is selected from one of 4-N,N-dimethylpyridine (DMAP) or 1-hydroxybenzotriazole (HOBT), and the reaction temperature of the amidation reaction is 0℃-25℃.
[0046] 7. The preparation method as described in item 4, wherein the reaction solvent for the reductive amination reaction in step (1) is a haloalkane, preferably dichloromethane; the base is one or more of trimethylamine, triethylamine, DIPEA, and DBU, preferably triethylamine; the reducing agent for the reductive amination reaction is selected from one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride, preferably sodium triacetoxyborohydride; and the reaction temperature is 0℃-25℃, preferably 25℃.
[0047] 8. The preparation method as described in item 4, wherein the base for the amidation reaction in step (2) is selected from triethylamine or pyridine, with triethylamine being preferred; the amide condensing agent is selected from one of dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), with EDCI being preferred; the condensation activator is selected from one of 4-N,N-dimethylpyridine (DMAP) or 1-hydroxybenzotriazole (HOBT), with DMAP being preferred; and the reaction temperature of the amidation reaction is 0℃-25℃, with 25℃ being preferred.
[0048] Using the preparation method described in item 4 above, compounds of formulas I, II, and III (corresponding to compounds T-29, T-66, and T-34 of the embodiments of this disclosure, respectively) can be prepared. Compound 1 (2.09 mmol, 1.0 eq), triethylamine (8.38 mmol, 4.0 eq), and dichloromethane were added to a reaction flask and stirred at room temperature for 30 minutes. Then, 3-fluorobenzaldehyde or 3,5-bis(trifluoromethylbenzaldehyde) (2.51 mmol, 1.2 eq) was added to the mixture, and the reaction was stirred at room temperature for 30 minutes. Then, sodium triacetoxyborohydride (8.38 mmol, 4.0 eq), a reducing agent, was added, and the mixture was stirred for another 10 hours. The reaction was then monitored by TLC. After the reaction was completed, the pH was adjusted to 9 with sodium carbonate aqueous solution. An appropriate amount of dichloromethane was added to the reaction flask, and the mixture was extracted three times with saturated brine. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was evaporated to obtain the crude product. The crude product was then purified by column chromatography (V(DCM):V( / MeOH) = 70:1) to obtain the target compounds I and II in 85% and 90% yields, respectively.
[0049] Compound 1 (2.09 mmol, 1.0 eq), triethylamine (8.38 mmol, 4.0 eq), and dichloromethane were added to the reaction flask. After stirring at room temperature for 30 minutes, 2,4-dichloro-5-fluorobenzoic acid (2.51 mmol, 1.2 eq), EDCI (2.51 mmol, 1.2 eq), and HOBT (2.51 mmol, 1.2 eq) were added to the mixture. After stirring at 25 °C for 10 hours, dichloromethane was added to the reaction flask. The organic phase was extracted three times with saturated brine, dried over anhydrous sodium sulfate, filtered, and the filtrate was evaporated to dryness to obtain the crude product. The crude product was purified by column chromatography (V(DCM):V / (MeOH) = 70:1) to obtain the target compound III in 85% yield.
[0050] Beneficial effects of this disclosure
[0051] The disclosed compounds exhibit excellent TRPV1 antagonistic activity and can be used to prevent, treat, or improve various diseases related to TRPV1 activity.
[0052] Specifically, the diseases include pain disorders such as chronic pain, neuropathic pain (including traumatic pain, diabetic pain, metabolic pain, infectious pain, toxic pain, cancer treatment-induced pain, or iatrogenic pain), arthritic pain, rheumatic pain, fibromyalgia, back pain, cancer-related pain, facial neuralgia, headache, migraine, toothache, burn pain, postherpetic neuralgia, muscle pain, central or peripheral nerve compression pain, spinal cord or brain trauma pain, spinal cord or brain ischemic pain, neurodegenerative pain, pain after spinal cord or brain hemorrhage cerebrovascular accident, or post-shock pain, etc.; as well as chronic cough, asthma or airway hyperresponsiveness, dermatitis-related pruritus (such as atopic dermatitis or psoriasis-related pruritus), etc.
[0053] This disclosed compound not only exhibits good TRPV1 target activity and selectivity, but also excellent oral bioavailability and significant pharmacodynamic activity in various in vivo pain and epilepsy models. More importantly, this disclosed compound does not cause an increase in body temperature and has no significant cardiac safety risk, thus possessing a wider safety window.
[0054] In summary, the disclosed compound overcomes many shortcomings of existing TRPV1 antagonists, possessing high activity, high bioavailability, and excellent safety, and is expected to achieve better therapeutic effects, showing promising clinical application prospects.
[0055] The compounds of formulas I, II, and III disclosed herein have shown definite and excellent therapeutic effects in the treatment of convulsions or epilepsy:
[0056] The compounds of Formula I, Formula II, and Formula III disclosed herein all contain a basic core structure of "2-piperidine-substituted imidazopyridine nitrogen heterocycle". After introducing specific substituents into this core structure, the resulting compounds exhibit excellent therapeutic effects in treating and / or preventing various types of epileptic seizures in animals (including humans). Compounds of Formula I and Formula III show significant inhibitory effects on convulsions induced by subcutaneous injection of pentylenetetrazol, effectively counteracting pentylenetetrazol-induced epileptic seizures; while compound of Formula II shows outstanding blocking effects on tonic seizures induced in a maximal electroconvulsive model. Attached Figure Description
[0057] Figure 1 shows the dose-response curves of the compound T-34 and the positive control drug AMG517 of this disclosure on the activity of capsaicin and the TRPV1 channel activated by acidic solution.
[0058] Figure 2 shows the effect of compound T-34 of this disclosure on recombinant cardiac ion channel currents, including hERG potassium channel, Cav1.2 calcium channel, KCNQ1 / E1 potassium channel, Kv4.3 potassium channel and Nav1.5 sodium channel.
[0059] Figure 3 shows the effect of compound T-34 of this disclosure on action potential parameters of guinea pig ventricular myocytes.
[0060] Figure 4 shows the analgesic effect of a single dose of compound T-34 of this disclosure on formalin-induced inflammatory pain.
[0061] Figure 5 shows the analgesic effect of a single dose of compound T-34 of this disclosure on acute inflammatory pain induced by Freund's complete adjuvant (CFA).
[0062] Figure 6 shows the analgesic and relieving effect of multiple doses of compound T-34 administered by gavage on capsaicin-induced acute pain.
[0063] Figure 7 illustrates the analgesic effect of continuous multiple-dose oral administration of compound T-34 of this disclosure on chronic inflammatory pain induced by Freund's complete adjuvant (CFA).
[0064] Figure 8 shows the effect of intraperitoneal injection of compounds T-34 and AMG517 of this disclosure on the core body temperature of mice.
[0065] Figure 9 shows the effect of compound T-34 of this disclosure on core body temperature under pathological conditions of chronic inflammatory pain induced by Freund's complete adjuvant (CFA) after multiple doses administered by gavage. Detailed Implementation
[0066] The present disclosure will be further described in detail below with reference to specific embodiments, but these embodiments do not limit the scope of protection of the present disclosure.
[0067] I. Examples of Compound Preparation
[0068] Preparation Example 1
[0069] 2,3-Diaminopyridine (18.32 mmol)¹ and 1-(tert-butyloxycarbonyl)piperidin-4-carboxylic acid (27.48 mmol)² were dissolved in N,N-dimethylformamide (DMF), followed by the addition of carbonyl diimidazole (CDI, 27.48 mmol) and pyridine (54.98 mmol). The mixture was heated to reflux for 20 hours, and the reaction was monitored by thin-layer chromatography (TLC). After the reaction was complete, the mixture was cooled to room temperature. Deionized water (50 mL) was added to the solution, and the mixture was extracted with ethyl acetate (50 mL × 3). All organic phases were combined and washed with saturated brine (40 mL × 3). The organic phases were dried over anhydrous sodium sulfate and filtered. The filtrate was concentrated under reduced pressure to remove the solvent. The crude product was purified by column chromatography using dichloromethane / methanol as the eluent, yielding the target product 3 as a white solid in 80% yield. 1 H NMR (500MHz, DMSO-d6): 12.77(s,1H),8.26(d,J=4.1Hz,1H),7.89(d,J=7.5Hz,1H),7.17(dd,J=7.9,4.8Hz,1H),4.01(d,J=12 .0Hz,2H),3.10-3.06(m,1H),2.93(s,2H),2.00(dd,J=13.0,2.5Hz,2H),1.70(qd,J=12.0,4.2Hz,2H),1.42(s,9H).HRMS(ESI + ):[M+H] + 303.1830.
[0070] Preparation Examples 2 to 6
[0071] In Examples 2 to 6, the products were prepared using the same method as in Example 1, following the steps of Example 1. Specifically, 1-(tert-butyloxycarbonyl)piperidine-4-carboxylic acid was replaced with tert-butyl2-(3H-imidazo[4,5-b]pyridin-2-yl)piperidine-1-carboxylic acid ester, tert-butyl3-(3H-imidazo[4,5-b]pyridin-2-yl)piperidine-1-carboxylic acid ester, tert-butyl2-(3H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylic acid ester, tert-butyl3-(3H-imidazo[4,5-b]pyridin-2-yl)pyrrolidine-1-carboxylic acid ester, and tert-butyl3-(3H-imidazo[4,5-b]pyridin-2-yl)azaidine-1-carboxylic acid ester. The 1H NMR and high-resolution mass spectrometry data of the products are shown in Table 1.
[0072] Preparation Examples 7-8
[0073] In Examples 7-8, the preparation was carried out using the same method as in Example 1, following the steps of Example 1. The only difference was that pyridine-2,3-diamine was replaced with o-phenylenediamine or other aryl diamines.
[0074] Table 1. Structures, 1H NMR spectra, and high-resolution mass spectrometry data of the products from Examples 1-9
[0075] Preparation Example 9
[0076] Compound 3 (18.32 mmol, 1.0 eq) was dissolved in ethyl acetate (30 mL). HCl / EA solution (6 mol / L, 30 mL) was slowly added dropwise to the reaction system while cooling in an ice-water bath (0 °C). After the addition was complete, the ice bath was removed, and the reaction mixture was allowed to warm naturally to room temperature. The mixture was then stirred at room temperature for 12 hours. After the reaction was complete, a pale yellow solid was collected by vacuum filtration to obtain compound 4, which was used directly in the next reaction. Triethylamine (8.38 mmol, 4.0 eq) was added to a solution of compound 4 (2.09 mmol, 1.0 eq) in dichloromethane (10 mL). The mixture was stirred at room temperature for 30 minutes, followed by the addition of o-fluorobenzaldehyde (2.51 mmol, 1.2 eq). After stirring for another 30 minutes, sodium triacetoxyborohydride (STAB, 8.38 mmol, 4.0 eq) was added. The resulting mixture was stirred at room temperature for 8 hours and monitored by TLC. After the reaction was complete, an aqueous sodium carbonate solution was added to the reaction mixture to adjust the pH to 9. The reaction mixture was poured into a mixture of 20 mL dichloromethane and 10 mL brine. The organic layer was separated, washed with brine (2 x 20 mL), dried over anhydrous sodium sulfate, filtered, and concentrated. The residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 70:1) to give the target compound in 75% yield. 1H NMR (500MHz, DMSO-d6): δ12.77(s,0.6H),12.42(s,0.4H),8.30(d,J=4.0Hz,0.4H ),8.22-8.21(m,0.6H),7.92-7.91(m,0.6H),7.80(d,J=7.3Hz,0.4H),7.44(t,J=6 .7Hz,1H),7.35-7.31(m,1H),7.21-7.13(m,3H),3.57(s,2H),2.92-2.81(m,3H),2 .15(dd,J=20.8,10.0Hz,2H),2.00(d,J=12.7Hz,2H),1.89-1.82(m,2H).HRMS(ESI + ):[M+Na] + 333.1499.
[0077] Preparation Examples 10 to 33
[0078] In Examples 10 to 33, the same method as in Example 9 was used, except that X and Y in compound 3 were combined differently, and m-fluorobenzaldehyde was replaced with the corresponding aromatic aldehyde to obtain the target compounds. The structures, 1H NMR spectra, and HRMS data of the target compounds in Examples 10-33 are shown in Table 2.
[0079] Preparation Example 34
[0080] Compound 3 (18.32 mmol, 1.0 eq) was dissolved in ethyl acetate (30 mL) and cooled in an ice-water bath (0 °C). HCl / EA solution (6 mol / L, 30 mL) was slowly added dropwise to the reaction mixture. After the addition was complete, the ice bath was removed, and the reaction mixture was allowed to warm naturally to 25 °C. The mixture was then stirred at 25 °C for 12 hours. After the reaction was complete, a pale yellow solid was collected by vacuum filtration to give compound 4, which was used directly in the next reaction step. Triethylamine (8.38 mmol, 4.0 eq) was added to a solution of compound 4 (2.09 mmol, 1.0 eq) in 10 mL of dichloromethane and stirred at room temperature for 30 minutes. Then, 2,4-dichloro-5-fluorobenzoic acid (2.51 mmol, 1.2 eq), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (EDCI, 2.51 mmol, 1.2 eq), and 1-hydroxybenzotriazole (HOBT, 2.51 mmol, 1.2 eq) were added. The mixture was stirred at room temperature for 5–8 hours and monitored by TLC. After the reaction was complete, the reaction mixture was poured into a mixture of 20 mL of dichloromethane and 10 mL of brine. The organic layer was separated, washed with brine (2 × 20 mL), and dried over anhydrous sodium sulfate. After filtration, the organic phase was concentrated, and the residue was purified by silica gel column chromatography (eluent: dichloromethane / methanol = 70:1) to obtain the target compound in 80% yield. 1 H NMR (500MHz, DMSO-d6): δ12.87(s,0.6H),12.51(s,0.4H),8.26(s,1H),7.95 (d,J=6.5Hz,2H),7.65(dd,J=26.9,8.9Hz,1H),7.18(dd,J=7.9,4.8Hz,1H),4 .51(t,J=14.1Hz,1H),3.42(d,J=2.8Hz,1H),3.27-3.18(m,2H),3.12-3.06(m ,1H),2.17(t,J=11.4Hz,1H),2.05-1.98(m,1H),1.91-1.78(m,2H).HRMS(ESI + ):[M+Na] + 415.0510.
[0081] Preparation Examples 35 to 40
[0082] In Examples 35 to 40, the same method as in Example 34 was used, except that X and Y in compound 3 were combined differently, and 2,4-dichloro-5-fluorobenzoic acid was replaced with the corresponding aromatic acid to obtain the target compound. The structure, 1H NMR spectrum, and HRMS data of the target compounds in Examples 35-40 are shown in Table 2.
[0083] Table 2. Structures, 1H NMR spectra, and high-resolution mass spectrometry data of products from Examples 9-40
[0084] II. Target Testing Examples
[0085] Example 1 of target testing experiment: The study of the compound disclosed herein mainly used the TRPV1 channel expressed on human embryonic kidney HEK293 cells to perform FLIPR calcium flow experiment and patch clamp electrophysiological experiment.
[0086] 1. Detection of the activity of compounds against capsaicin-activated TRPV1 receptors using the FLIPR calcium flow method.
[0087] The stable TRPV1-HEK293 cell line was routinely cultured in DMEM medium containing 10% FBS and 500 μg / mL G418. One day prior to the experiment, TRPV1-HEK293 cells that had reached approximately 80% confluence were seeded into 384-well black-bottomed permeable cell culture plates (NUNC 142761) pre-coated with 0.1 mg / mL PDL, with 2.5 × 10⁶ cells per well. 4 Each cell plate was inoculated with 30 μL of the culture medium. The cell plates were then incubated overnight at 37°C in a 5% CO2 incubator.
[0088] The following day, the culture medium in each well was discarded, and 20 μL of FLIPR Calcium 6 fluorescent dye was added to each well. The cells were incubated at 37°C in the dark for 1 hour. While the cells were incubating with the dye, five-fold concentrations of the test compound were freshly prepared in 384-well compound plates (Corning 3657): for example, when the final concentration of the compound was 10 μM, a concentration of 50 μM was prepared in the compound plate. The compound was serially diluted three-fold starting from the highest concentration, with at least four replicates for each concentration. The samples were then analyzed using a real-time fluorescence detection system (FLIPR). TetraCompound (5 μL) was applied to each well using a liquid sampler from Molecular Devices. The compound was incubated with the cells for 20 minutes. A combination of excitation wavelength (470-495 nm) and emission wavelength (515-575 nm) was used to detect calcium flow signals. The detection procedure was as follows: a baseline reading was taken for 10 seconds (F0), and at the 11th second, the agonist capsaicin was added to a final concentration of 10 nM to activate the TRPV1 channel; thereafter, readings were taken once per second for 120 seconds (F).
[0089] The activity of the compound was calculated based on the quantitative fluorescence intensity output by FLIPR, and normalized using the fluorescence value of the capsaicin control well as a reference to obtain the inhibition rate of the compound on fluorescence intensity at different concentrations. If a dose-dependent inhibition of activity was observed, the half-maximal inhibitory concentration (IC50) was determined. 50 If there is no dose-dependent inhibition, the percentage change in activity at the highest tested concentration is displayed.
[0090] 2. Patch-clamp electrophysiological method for evaluating the effect of compounds on TRPV1 receptor activity
[0091] Whole-cell voltage-clamp recordings were performed at room temperature using an EPC-10 amplifier (HEKA Electronic, Lambrecht, Germany). HEK293 cells stably expressing TRPV1 were used as the experimental subjects. Data acquisition was performed using PatchMaster software at a sampling frequency of 20 kHz and a filtering frequency of 2 kHz. The extracellular fluid composition (mM) was: 140 NaCl, 3 KCl, 2 MgCl2, 2 CaCl2, 10 HEPES, and 10 Glucose, with the pH adjusted to 7.40 using NaOH. The electrode intraelectrode composition (mM) was: 140 NaCl, 2 MgCl2, 5 EGTA, and 10 HEPES, with the pH adjusted to 7.30 using NaOH. A VC3-8PG perfusion drug delivery system was used. Before drug administration, cells were perfused with extracellular fluid. After the cells stabilized for 3–5 minutes, the effect of the compound on the TRPV1 channel current activated by capsaicin was measured. Cells were clamped at 0 mV and stimulated using a ramp stimulation program lasting 500 ms (voltage from -100 mV to +100 mV) to induce TRPV1 currents by administering 10 nM capsaicin. The activity of the compound is expressed as the inhibition rate of the capsaicin-activated current (100% * (Icap - Idrug) / Icap). If dose-dependent inhibition of activity was observed, the half-maximal inhibitory concentration (IC50) was determined. 50 If there is no dose-dependent inhibition, the percentage change in activity at the highest tested concentration is shown.
[0092] 3. Experimental Results: As shown in Table 3, the table is explained below:
[0093] (1) Inh%at 30μM@FLIPR assay, representing the inhibition rate of the compound at a concentration of 30μM against the TRPV1 activity induced by capsaicin at 10nM in the FLIPR calcium flow method analysis;
[0094] (2) Inh% at 30μM or IC 50 (μM)@patch clamp assay represents the inhibition rate or IC50 of a compound at a concentration of 30 μM against TRPV1 activity induced by 10 nM capsaicin in patch clamp electrophysiological recordings. 50 value.
[0095] (3) Agonist (percentage): The activity of the compound in activating the TRPV1 channel, expressed as a percentage of the activity activated by 10 nM capsaicin (100 x 10^6). drug / I Cap )
[0096] Table 3. Effects of compounds on TRPV1 receptors tested using the FLIPR calcium flow method and patch-clamp electrophysiological method.
[0097] Example 2 of target testing experiment: Comparison of the blocking activities of compounds T-34 and AMG-517 on capsaicin-activated and acid-activated TRPV1 channels.
[0098] The experimental procedures were the same as those in Example 1 of the target testing experiment. This experiment first used the Hill equation to fit the dose-dependent curve of the disclosed compound T-34, and the experimental results are shown in Figure 1.
[0099] Experimental results: As shown in Figure 1, both T-34 and AMG517 exhibited good inhibitory activity in activating the TRPV1 channel current with capsaicin: IC 50 =0.11±0.05μM(T-34) (Figure 1A), IC 50 =0.60±0.12 nM (AMG517) (Figure 1B). Although T-34 activity was slightly weaker than that of AMG517, it showed good inhibitory activity compared to other TRPV1 inhibitors of the same type. During attempts to activate TRPV1 channels with an acidic solution (pH=5.5), the acidic environment exceeded the cells' tolerance limit, leading to rapid deterioration of cell state and making it difficult to record ion flow manually using patch clamp. Therefore, a milder acidic condition (pH=6.5) was used to activate TRPV1 channels to evaluate the inhibitory activity of the compounds. IC50 of AMG517 was... 50Compared to 1.73 ± 0.32 nM (Figure 1D), T-34 showed no significant inhibitory effect on the acid activation of TRPV1, with an IC50 value of 1.73 ± 0.32 nM. 50 >30μM (Figure 1C)
[0100] Example 3 of target testing experiment: Activity test of compound T-34 on other pain-related targets
[0101] The experimental procedure is the same as that of the patch-clamp electrophysiological experiment in Example 1 of the target testing experiment.
[0102] The culture conditions for each target cell line were as follows: all cells were cultured in a 37°C, 5% CO2 incubator. Cell lines constructed from HEK293 cells were cultured in DMEM medium containing 10% FBS, while cell lines constructed from CHO-K1 cells were cultured in DMEM / F-12 medium containing 10% FBS. Screening antibiotics were added to both media according to the resistance requirements of the respective cell lines.
[0103] Specifically: TRPV3-HEK293 and TRPM8-HEK293 were supplemented with 500 μg / mL G418; TRPA1-Flp-In TM T-Rex 293 cells were supplemented with 100 μg / mL Hygromycin B and 10 μg / mL Blaticidin, and tetracycline (1.0 μg / mL) was added the night before the experiment for induction; Cav3.2-HEK293 cells were supplemented with 1000 μg / mL G418; stable cell lines of Cav3.1-HEK-FlpIn-293 and P2X7-HEK-FlpIn-293 were supplemented with 100 μg / mL Hygromycin B; Cav2.2 / β3 / α2δ1-HEK293 cells were supplemented with 100 μg / mL Hygromycin B, 10 μg / mL Blasticidin, 100 μg / mL Zeocin, and 0.5 μg / mL Puromycin; Nav1.7-Flp-In TM -293 Add 300 μg / mL Hygromycin B; α1β2γ2-GABA A RT-Rex TM -CHO was supplemented with 10 μg / mL Blasticidin, 300 μg / mL Hygromycin B, 100 μg / mL Zeocin, and 1 μg / mL Puromycin; GlyRαl-Flp-In TM -CHO is supplemented with 300 μg / mL Hygromycin B; KCNQ2-CHO is supplemented with 500 μg / mL G418.
[0104] Experimental Results: The target selectivity of T-34 is shown in Table 4. For members of the TRP channel family, the main subtypes tested were TRPV3, TRPA1, and TRPM8. The results showed that T-34 at 30 μM had no significant effect on these three TRP channels.
[0105] To investigate the effect of T-34 on calcium channel subtypes, we tested four calcium channel subtypes: Cav2.1, Cav2.2, Cav3.1, and Cav3.2. The results showed that T-34 had weak inhibitory effects on both the resting and inactivated states of Cav2.1 channels, with an IC50 value of [missing value]. 50 All concentrations were greater than 30 μM; the inhibitory effect on the resting state of Cav2.2 channels was not significant, but it had a significant inhibitory effect on the inactivated state, with an IC50 concentration of 30 μM. 50 =10.52±1.84μM; The resting-state inhibition effect on the Cav3.1 channel is relatively weak. 50 >30μM, for inactivated IC 50 The concentration was 10.78 ± 2.00 μM; notably, T-34 exhibited the strongest inhibitory effect on the inactivated state of the Cav3.2 channel, with an IC50 concentration of 10.78 ± 2.00 μM. 50 As low as 7.16±1.64μM, while for resting-state IC50 50 >30 μM. The above results indicate that the inhibitory intensity of T-34 on calcium channel subtypes is ranked as follows: Cav3.2 > Cav2.2 > Cav3.1 > Cav2.1, and the inhibitory effect on all sensitive subtypes shows a significant inactivation-dependent relationship. This selectivity spectrum suggests that T-34 may exert its pharmacological activity by inhibiting calcium channels while targeting the main analgesic target TRPV1.
[0106] Further testing was conducted on the T-34's GABA response. A1 The effects of T-34 on targets such as receptors (α1β2γ2), α1Gly-R glycine receptor, KCNQ2 potassium channel, P2X7 receptor, and Nav1.7 sodium channel were investigated. The results showed that T-34 had no effect on these channels or had weak activity at the maximum test concentration of 30 μM.
[0107] Table 4. Target-selective activity of T-34 on pain-related ion channels
[0108] III. Experimental Examples Related to Cardiac Safety
[0109] Example 1 of cardiac safety-related experiments: Activity test of compound T-34 on cardiac safety-related ion channels
[0110] The experimental procedures were the same as those in Example 1 of the target testing experiment. To clarify the cardiac safety of T-34, this study used the whole-cell patch-clamp method to analyze the in vitro arrhythmogenic risk of compound T-34. The cell culture conditions for each target were as follows: the hERG-CHO-K1 stable cell line was cultured in DMEM / F-12 medium containing 10% FBS, supplemented with 200 μg / mL Hygromycin B and 200 μg / mL G418. The Cav1.2-HEK293 stable cell line was cultured in DMEM medium containing 10% FBS, supplemented with 100 μg / mL Hygromycin B, 100 μg / mL G418, and 40 μg / mL Zeocin. Nav1.5-HEK293 and Kv4.3-HEK293 cells were cultured in DMEM medium containing 10% FBS, supplemented with 500 μg / mL G418. KCNQ1 / KCNE1 plasmids were co-transfected into CHO-K1 cells at a mass ratio of 1:1, and electrophysiological recordings were performed 24 hours after transfection.
[0111] Experimental Results: First, the effects of T-34 on the key ion channels hERG and Cav1.2 in cardiac action potential were examined. The results showed that T-34 had an effect on the IC50 of hERG. 50 =9.83±1.29μM (IC) 50-hERG / IC 50-TRPV1 ≈89 times), IC50 of inactivated Cav1.2 50 17.65 μM (IC) 50-Cav1.2 / IC 50-TRPV1 (≈160 times). It is known that simply blocking hERG potassium channels may prolong the QT interval and increase the risk of torsades de pointes (TdP); while blocking Cav1.2 alone may be accompanied by a risk of QT interval shortening. If the compound acts on both channels simultaneously, their prolongation and shortening effects may cancel each other out, potentially reducing the risk of TdP to some extent. Based on these results, it is preliminarily suggested that T-34 exerts its pharmacological effects while having a relatively low risk of adverse cardiac reactions, but its clinical safety still needs to be comprehensively evaluated with more data. To further clarify its effects on other cardiac ion channels, we further examined Nav1.5, Kv4.3, and KCNQ1 / KCNE1 channels. The results showed that T-34 did not exhibit significant inhibitory effects on these channels. Specific results are shown in Figure 2 and Table 5.
[0112] Table 5. Effects of T-34 on cardiac safety-related ion channel currents
[0113] Example 2 of cardiac safety-related experiments: Effects of compound T-34 on action potential parameters of guinea pig ventricular myocytes
[0114] The method for isolating guinea pig ventricular myocytes was based on and modified from the literature (Circ Res. 2016 Sep 30; 119(8):909-20). The relevant solution formulations are as follows:
[0115] EDTA buffer (mM): NaCl 130, KCl 5, NaH2PO4 0.5, HEPES 10, D-Glucose 10, BDM 10, Taurine 10, EDTA 5. Adjust pH to 7.8 with NaOH, then filter sterilize.
[0116] Perfusion buffer (mM): NaCl 130, KCl 5, NaH2PO4 0.5, HEPES 10, D-Glucose 10, BDM 10, Taurine 10, MgCl 1. Adjust pH to 7.8 with NaOH and sterilize by filtration.
[0117] Collagenase digestion solution: This digestion solution is prepared with perfusion buffer, prepared fresh for each use, and filtered for sterilization. The components include: Collagenase 2 0.5 mg / ml (Worthington, USA); Collagenase 4 0.5 mg / ml (Worthington, USA); Protease XIV 0.05 mg / ml (Sigma, USA).
[0118] Termination solution: perfusion buffer containing 5% fetal bovine serum.
[0119] Inoculation medium: M199 medium supplemented with 5% fetal bovine serum, 10mM BDM and penicillin / streptomycin.
[0120] Male guinea pigs (weighing 250g-300g) were anesthetized by inhalation with chlorofluoroethane using a small animal anesthesia machine (Reward, China). Complete anesthesia was confirmed by observing a decrease in respiratory rate and the disappearance of the toe-clamping reflex. After disinfecting the guinea pig's chest with 70% ethanol, the thoracic cavity was opened below the diaphragm to expose the heart. The descending aorta and inferior vena cava were severed, and 7ml of EDTA buffer was injected into the base of the right ventricle within 1 minute. At this point, the heart rapidly stopped beating and its color lightened. The ascending aorta was clamped, and after severing the vessel, the heart was transferred to a culture dish containing EDTA buffer, ensuring it was almost completely submerged. 7ml of EDTA buffer (flow rate 2-3ml / min) was injected through the left ventricular wall (2-3mm above the apex), followed by rinsing with perfusion buffer to remove residual EDTA. The heart was then transferred to collagenase digestion solution, and preheated collagenase solution was circulated through the left ventricle above the apex until the heart softened and the perfusion fluid became stringy, at which point digestion was terminated. After digestion, the left ventricle is removed, placed in fresh collagenase buffer, and shredded to approximately 1 mm. 3 The tissue block was gently pipetted for 2 minutes using a wide-mouth pipette tip. The enzyme reaction was terminated by adding stop solution, and the mixture was filtered through a 100μm filter and allowed to settle by gravity for 20 minutes. Calcium was then gradually recalcified in three steps (Ca). 2+ The final concentrations were 0.34, 0.68, and 1.02 mmol / L, respectively. The isolated cardiomyocytes were then seeded onto coverslips pre-coated with laminin (GIBCO) at a concentration of 50 μg / ml. Cells were cultured at 37°C and could be used for patch-clamp experiments 2 hours after adhesion. Recording results were optimal within 6-8 hours after isolation.
[0121] Action potentials were recorded using the HEKA EPC10 amplifier in current-clamp mode. The extracellular fluid composition (mM) was as follows: 140 NaCl, 3 KCl, 1.5 MgCl2, 2 CaCl2, 10 HEPES, 10 Glucose. After thorough mixing, NaOH was added to adjust the pH to 7.4. The electrode intraelectrode composition (mM) was as follows: 145 KCl, 1 MgCl2, 5 EGTA, 10 HEPES, 5 MgATP. After thorough mixing, KOH was added to adjust the pH to 7.3, and sucrose was added to adjust the osmotic pressure to 290–300 mOsm. The mixture was filtered through a 0.22 μM filter membrane.
[0122] In the experiment, the cell clamping current was set to 0 pA, and an injection current with a duration of 10 ms was applied to induce action potentials, followed by recording action potentials with a duration of 1 s. A thermostatic perfusion system (CC-28, Warner) was used to heat the bath solution to 32°C, with a perfusion rate of 1-2 ml / min. For each concentration of compound, perfusion was performed for 3-5 min. 20-30 action potentials were continuously recorded after administration, and the average value was used for data analysis. Statistical indicators included the 50% and 90% action potential duration (APD). 50 APD 90 Action potential amplitude (APA) and resting membrane potential (RMP).
[0123] Experimental results: As shown in Figure 3, within the concentration range of 0.3–30 μM, T-34 showed a significant effect on action potential duration (APD). 50 APD 90 The action potential amplitude and resting membrane potential were not significantly affected by T-34. In this study, T-34 blocked the IC50 of hERG. 50 The IC is 9.8 μM, for Cav1.2. 50 At a concentration of 17.65 μM, the effects of these two actions on action potential duration may cancel each other out. The APD prolongation effect caused by hERG blockade and the APD shortening effect caused by Cav1.2 blockade are antagonistic, resulting in no significant net effect on APD. In conclusion, within the effective concentration range, the risk of T-34 inducing arrhythmias is relatively low.
[0124] IV. Implementation of in vivo efficacy evaluation of compounds
[0125] Example 1: Evaluation of the effect of the compound on formalin-induced inflammatory pain
[0126] Male CD-1 mice (25-30g) were randomly divided into three groups: a solvent control group, a pregabalin (30mg / kg, po) positive control group, and a T-34 (10mg / kg, ip) group, with eight mice in each group. Thirty minutes after gavage administration, each group underwent a subcutaneous injection of 20μL of 2.5% formalin solution (using physiological saline as the solvent) into the right hind paw to induce a paw irritation model. Mice were placed in a transparent plexiglass observation box, and behavioral changes in licking the right hind paw were continuously recorded for 60 minutes post-injection. The cage consisted of three mirrored walls and one transparent wall to provide an unobstructed view of the mouse's paw. Based on the characteristics of the pain response, the observation period was divided into two phases for statistical analysis: phase one (peripheral acute stimulation, 0-10 min) and phase two (central sensitization and inflammation, 10-60 min). The cumulative time (sec) of paw licking was recorded in each phase, and the inhibitory effect of the drug on different types of pain was evaluated based on the cumulative time.
[0127] Experimental Results: As shown in Figure 4, T-34 exhibits selective inhibitory characteristics against formalin-induced biphasic pain. In the first phase of pain, neither 10 mg / kg T-34 nor 30 mg / kg pregabalin showed significant analgesic activity, and the time mice spent licking their paws was not significantly different from the model group, suggesting that T-34 has limited effect on direct chemical noxious stimuli. Notably, in the second phase of pain, 10 mg / kg T-34 significantly reduced the time mice spent licking their paws, demonstrating clear analgesic activity (Figure 4, p < 0.001), with an effect comparable to that of 30 mg / kg pregabalin in this phase.
[0128] Example 2: Evaluation of the effect of the compound on inflammatory pain induced by complete Freund's adjuvant.
[0129] Male CD-1 mice (25-30g) were selected, and 20 μL of complete Freund's adjuvant (CFA; diluted 1:1 with physiological saline) was subcutaneously injected into the plantar side of the right hind paw to induce inflammatory pain. Twenty-four hours after CFA injection, the animals were randomly divided into the following groups (n=6 per group): solvent control group, pregabalin positive control group (30 mg / kg, administered by gavage), and T-34 group (30 mg / kg, administered by gavage). The solvent control solution was formulated as physiological saline containing 30% (w / v) 2-hydroxypropyl-β-cyclodextrin, with the addition of 5% DMSO and 1% Tween-80. The following behavioral tests were performed before CFA injection, 24 hours after CFA injection (i.e., before administration), and 60 minutes after administration.
[0130] Thermal hyperalgesia in mice was assessed using a modified Hargreaves method (Ugo Basile, model 37370). For three consecutive days prior to the test, mice were placed in an acrylic glass chamber with a glass plate for 30 minutes each day to acclimatize. On the day of the experiment, after 30 minutes of acclimatization, radiant heat stimulation was applied to the right hind paw from below the glass plate, and the paw withdrawal latency was recorded. Each mouse underwent the test three times, with at least 3 minutes between each test, and the average value was taken as the final paw withdrawal latency. The radiant heat stimulation cutoff time was set to 20 seconds to prevent tissue damage.
[0131] The effects of the compound on CFA-induced mechanosensitive hyperalgesia were evaluated using a tactile response assay (Ugo Basile, model 37450). The procedure was briefly as follows: Mice were placed above a perforated metal plate, each individually in a plexiglass chamber above the stimulation device. A mechanosensitive stimulation needle was carefully applied to the center of the right hind paw of each mouse. An upward force was applied with the needle in a gradually increasing manner, linearly increasing from 0g to 10g over 20 seconds. The applied force at which a withdrawal response occurred in the right hind paw of each mouse was recorded. Measurements were repeated three times for each mouse, and the mean value was used as the withdrawal threshold.
[0132] Experimental Results: As shown in Figure 5, T-34 significantly inhibited both CFA-induced mechanical and thermal hyperalgesia. In the thermal pain threshold test, 30 mg / kg T-34 significantly prolonged the thermal withdrawal latency 1 hour after gavage administration (Figure 5A, p<0.01); in the mechanical pain threshold test, it also significantly increased the mechanical withdrawal threshold in mice (Figure 5B, p<0.001), and its analgesic effect was comparable to that of 30 mg / kg pregabalin.
[0133] Example 3: Evaluation of the effect of the compound on capsaicin-induced pain.
[0134] Male CD-1 mice weighing 25–30 g were randomly divided into three groups: a solvent control group, a positive control group (BCTC, a TRPV1 antagonist) group (30 mg / kg), and low, medium, and high dose T-34 groups (3, 10, and 30 mg / kg), with six mice in each group. All mice were administered the medication via gavage. Before the experiment, the heat pain threshold of the right hind paw was measured. One hour after gavage administration, 20 μL of capsaicin solution (concentration 50 μg / mL, i.e., 1 μg / mouse) was subcutaneously injected into the right hind paw to induce the model. Immediately after modeling, the mice were placed in a transparent observation box, and the cumulative time spent licking the paw within 5 minutes after injection was observed and recorded as an evaluation index of acute chemical stimulation pain response. At 60, 120, and 180 minutes after drug administration (the start time of capsaicin modeling), the modified Hargreaves method (Ugo Basile, model 37370) was used to assess thermal hyperalgesia in mice and determine the thermal pain threshold to evaluate the inhibitory effect of the drug on capsaicin-induced thermal hyperalgesia.
[0135] Experimental Results: T-34 significantly inhibited capsaicin-induced acute pain in a dose-dependent manner. In the evaluation of pain behavior, the 3 mg / kg dose group showed a weaker effect (p>0.05), the 10 mg / kg dose group showed a certain degree of reduction in paw-licking time (p>0.05), while the 30 mg / kg group significantly shortened the paw-licking time within 5 minutes after modeling (Figure 6A, p<0.001), and its analgesic effect was comparable to the positive control drug BCTC (TRPV1 inhibitor). In the evaluation of thermal hyperalgesia, the latency of paw withdrawal due to thermal stimulation in mice was positively correlated with the administered dose: the 30 mg / kg group significantly prolonged the paw withdrawal latency at multiple time points after modeling (Figures 6B and 6C, p<0.001), the 10 mg / kg group had a moderate effect (p<0.01), and the 3 mg / kg group had no significant effect (p>0.05), further confirming the dose-dependent analgesic activity of T-34. In summary, T-34 demonstrated a good in vivo analgesic effect in a capsaicin-induced mouse pain model.
[0136] Example 4: Evaluation of the effect of compound T-34 on chronic inflammatory pain induced by complete Freund's adjuvant.
[0137] Forty-two male CD-1 mice (25-30g) were randomly divided into a non-CFA model group (control group, n=6) and a CFA model group (n=36). Mice in the CFA group received a subcutaneous injection of 20 μL of complete Freund's adjuvant (CFA; diluted 1:1 with physiological saline) on the right hind paw to induce inflammatory pain. To maintain chronic pain, a second 20 μL of the same CFA solution was injected into the paw on day 7 after the first CFA injection. The control group received 20 μL of physiological saline. Twenty-four hours after the CFA injection, the animals were randomly divided into six groups (n=6 per group): a solvent control group, a pregabalin positive control group (30 mg / kg, administered by gavage), and different doses of T-34 (3, 10, 30, 60 mg / kg, administered by gavage). The solvent control solution was formulated as follows: physiological saline containing 30% (w / v) 2-hydroxypropyl-β-cyclodextrin, with the addition of 5% DMSO and 1% Tween-80. Thermal pain response and mechanodynia were measured before CFA injection (D0) and 24 hours after CFA injection (D1).
[0138] Starting from the third day after CFA injection modeling (D3), the solvent control, various dose groups of T-34, or pregabalin were administered by gavage daily for a total of 11 days. Changes in thermal pain and mechanical pain thresholds were measured every other day.
[0139] Experimental results: As shown in Figure 7, T-34 inhibited CFA-induced thermal pain and mechanical pain hypersensitivity in a dose-dependent manner. The analgesic effect reached a plateau at doses of 30 mg / kg and 60 mg / kg, which was basically equivalent to the dose of 30 mg / kg pregabalin.
[0140] Example 5: Evaluation of the effect of compound T-34 on body temperature in mice
[0141] Twenty-four male CD-1 mice (25-30g) were randomly divided into a solvent control group, an AMG517 group, and a T-34 group. AMG517, a TRPV1 antagonist found to cause fever in clinical trials, was used as a positive control. Each group received an intraperitoneal injection of either the solvent control, AMG517 (10mg / kg), or T-34 (10mg / kg), with eight mice in each group. Before the formal test, the mice's forehead hair was shaved. After acclimatizing to their cages for 2 hours, the basal forehead temperature was measured and recorded using a non-contact handheld infrared thermometer (SMART SENSOR, ST9450, China), followed by intraperitoneal injection. Body temperature changes were measured and recorded at 5, 15, 30, 45, 60, 75, 90, 105, 120, 135, 150, 165, and 180 minutes after administration. In addition, infrared images of mice were captured and recorded using a non-contact handheld infrared thermometer 45 minutes after administration.
[0142] Experimental Results: As shown in Figure 8, at the 45-minute time point, intraperitoneal injection of the positive control drug AMG517 (10 mg / kg) significantly increased the body temperature of mice, with an increase of approximately 2.2℃. In contrast, the same dose (10 mg / kg, intraperitoneal injection) of T-34 did not cause significant changes in mouse body temperature during continuous 180-minute temperature monitoring, with a change of only 0.1℃ at the 45-minute time point. These results indicate that T-34 does not affect the body temperature of experimental animals.
[0143] To further evaluate whether T-34 would cause changes in body temperature under painful pathological conditions, body temperature changes were continuously recorded for 120 minutes after administration of different doses via gavage in the CFA-induced chronic inflammatory pain model of Example 4. The results are shown in Figure 9. At all doses (3, 10, 30, 60 mg / kg), T-34 did not have a significant effect on body temperature.
[0144] Example 6: Detection of the antiepileptic activity of the compound in vivo.
[0145] 1. Animal preparation and compound formulation
[0146] Animal husbandry: Kunming white mice (20±2g each), half male and half female, were used. Before the experiment, the male and female mice were housed in separate cages with free access to food and water. The room was well-ventilated, kept at a constant temperature (22℃-25℃), and the relative humidity was controlled (around 50%). Normal room lighting was provided (12 hours of bright light, 12 hours of dark light). Mice were allowed free access to food particles (4% mineral mixture, 10% corn oil, 20% sucrose, 0.2% cellulose, 10.5% casein (95% pure), 54.3% starch, and water) to help them quickly become familiar with the experimental environment. Animal husbandry followed optimal standards to avoid unnecessary interference with the animals. The screening dose for the initial screening of the compounds' antiepileptic activity was 30mg / kg. All compounds and positive control drugs were dissolved in dimethyl sulfoxide (DMSO) during preparation, with an injection volume of 0.1mL / 20g. In the Sc-PTZ model, the dose of pentylenetetrazol was 85 mg / kg, dissolved in 0.9% physiological saline, and the injection volume was 0.2 mL / 20 g.
[0147] 2. Subcutaneous pentylenetetrazol-induced epilepsy model (Sc-PTZ)
[0148] The ability of the test compound to block pentylenetetrazole-induced clonic seizures or tonic seizures induced by electric shock can be interpreted as a measure of anticonvulsant efficacy. The prepared compound solution was injected intraperitoneally into mice (30 mg / kg), followed by a subcutaneous injection of pentylenetetrazole (85 mg / kg) 30 minutes later. The mice's responses were observed over the next 30 minutes. The number of clonic seizures (ranging from violent shaking or trembling of the limbs) and the number of tonic seizures (limbs pulling or pushing towards the body or stiffly, usually with maximum extension of the hind legs) were used as the criteria for determining the duration of the seizure. Data are shown in Table 6.
[0149] 3. Maximum Electronic Shock (MES) Model
[0150] The JTC-1 type convulsion and pain sensory stimulator was used for stimulation output. The voltage was set to 80V, with a single stimulus of 0.3s. The ears and jaws of the mice were moistened with 0.9% saline solution and clamped with alligator clips. The mice were suspended and relaxed before stimulation was administered. Mice exhibiting hind leg rigidity were used in the experiment. The test compound was administered intraperitoneally at a dose of 30mg / kg. The absence of significant hind limb rigidity and extension indicated that the test compound possessed anti-maximal electroconvulsive activity.
[0151] Experimental Results: Data are shown in Table 6. As shown in Table 6, in the MES model, compound T-66, administered at a dose of 30 mg / kg, demonstrated complete protection in all three test animals (3 / 3, 100%). In the Sc-PTZ model, compounds T-29 and T-34 showed complete protection (3 / 3, 100%). These results indicate that compound T-66 has a significant inhibitory effect on MES-induced tonic seizures, demonstrating clear and excellent antiepileptic activity; compounds T-29 and T-34 also significantly inhibited seizures induced by the Sc-PTZ model, similarly demonstrating clear and excellent antiepileptic activity.
[0152] Table 6. Activity evaluation of compounds in two animal models of epilepsy.
[0153] 3.4 Quantitative Activity Assay
[0154] Compounds that showed a 3 / 3 protective effect against mice in the initial screening were further subjected to quantitative activity testing, i.e., the median effective dose (EDT) was determined. 50 Table 7 lists the ED of the compounds and positive control drugs. 50 Measurement results.
[0155] Experimental Results: Table 7 lists the activity evaluation results of T-29, T-66, T-34, and other positive control compounds in the Sc-PTZ and MES animal models. Table 7 data show that in the subcutaneous pentylenetetrazol (Sc-PTZ) model, the ED50 of compounds T-29 and T-34 disclosed in this disclosure... 50 The values were 6.85 mg / kg and 6.37 mg / kg, respectively, both lower than the positive control drugs phenobarbital and valproic acid, indicating that its anticonvulsant effect was significant and superior to the above control drugs; in the maximal electrical seizure (MES) model, the ED of compound T-66 was... 50 The value was 17.05 mg / kg, lower than the positive control drugs phenobarbital and sodium valproate, indicating that it has a significant blocking effect on electrically induced tonic seizures and has better activity.
[0156] Table 7. Quantitative test results of compound activity
[0157] a: Half-maximal effective dose b: 95% confidence interval (in parentheses)
[0158] V. Examples of Pharmacokinetic Studies
[0159] Example 1 of pharmacokinetic study: Evaluation of the pharmacokinetic characteristics of compound T-34
[0160] Male SD rats weighing 200-250g were selected. The animals were randomly divided into two groups, receiving either oral gavage or intravenous injection of compound T-34 at a dose of 30 mg / kg. Three rats (n=3) were included in each group at each time point. At 0.08, 0.17, 0.25, 0.5, 1, 2, 4, 6, 8, 10, 24, and 34 hours post-administration, approximately 300 μL of blood samples were collected via tail vein and placed in heparinized tubes. All blood samples were centrifuged at 12,000 rpm for 10 minutes at 4°C to separate plasma. 40 μL of plasma sample was added to 120 μL of acetonitrile solution containing 100 ng / mL internal standard (IS), and the mixture was vortexed for 1 minute to precipitate proteins. The sample was then centrifuged again at 12,000 rpm for 10 minutes at 4°C, and the supernatant was used for LC-MS / MS analysis.
[0161] Based on the obtained blood drug concentration data, pharmacokinetic parameters were calculated using a non-compartmental analysis (NCA) model. Key parameters included: time to peak concentration (T0). max ), peak concentration (C) max Elimination half-life (t1 / 2), area under the plasma concentration-time curve (AUC) 0-t and AUC 0- ∞), mean residence time (MRT), etc.
[0162] Experimental Results: The main pharmacokinetic parameters of T-34 administered to rats via gavage and intravenous injection (30 mg / kg) are summarized in Table 8. The results showed that the absolute bioavailability (F%) of T-34 administered via gavage was 32%. This result indicates that the compound is well absorbed orally and has potential for further development.
[0163] Table 8. Pharmacokinetic parameters of compound T-34 in rats after gavage and intravenous administration
Claims
1. A compound as shown in Formula A or a pharmaceutically acceptable salt thereof, in X is a nitrogen atom or -CH-; Y is One of them, in which the nitrogen atom is bonded to Z; Z is either -CH2- or -C(=O)- R1, R2, and R3 are each independently selected from hydrogen, halogen atoms, hydroxyl groups, methoxy groups, ethoxy groups, benzyloxy groups, cyano groups, trifluoromethyl groups, and nitro groups.
2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein, The compounds mentioned are selected from the following compounds:
3. The compound according to claim 1 or 2, or a pharmaceutically acceptable salt thereof, wherein, The pharmaceutically acceptable salt is a salt formed by the compound and an acid selected from at least one of maleic acid, succinic acid, citric acid, tartaric acid, fumaric acid, formic acid, acetic acid, propionic acid, malonic acid, oxalic acid, benzoic acid, phthalic acid, methanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, camphoric acid, camphorsulfonic acid, salicylic acid, hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, taurine, malic acid, lactic acid, and gluconic acid.
4. A method for preparing the compound according to any one of claims 1-3, comprising the following steps: Step a: o-aryldiamines 1 and 2 react with a condensing agent to form compound 3; Step b: Compound 3 is deprotected by the Boc protecting group to obtain compound 4 or its salt. Step c: Compound 4 or its salt reacts with an aryl aldehyde in the presence of a base and a reducing agent to produce the compound shown in formula A; Step d: Compound 4 or its salt reacts with an arylic acid in the presence of a base, an activator, and a condensing agent to produce the compound shown in formula A; 5. The method according to claim 4, wherein in step a, the condensing agent is selected from at least one of CDI, DCC, and EDCI; the reaction solvent is selected from at least one of DMF and DMAC; and the reaction temperature is 100℃-170℃.
6. The method according to claim 4, wherein in step b, the Boc protecting group is removed using one of hydrochloric acid, hydrogen chloride / ethyl acetate solution, or trifluoroacetic acid.
7. The method according to claim 4, wherein in step c, the base is one or more of trimethylamine, triethylamine, DIPEA, and DBU, the reducing agent for the reductive amination reaction is selected from one or more of sodium borohydride, potassium borohydride, sodium cyanoborohydride, or sodium triacetoxyborohydride, and the reaction temperature for the reductive amination reaction is 0℃-25℃.
8. The preparation method according to claim 4, wherein in step d, the base for the amidation reaction is selected from triethylamine or pyridine, the amide condensing agent is selected from one of dicyclohexylcarbodiimide (DCC), diisopropylcarbodiimide (DIC) or 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDCI), the condensation activator is selected from one of 4-N,N-dimethylpyridine (DMAP) or 1-hydroxybenzotriazole (HOBT), and the reaction temperature of the amidation reaction is 0℃-25℃.
9. A pharmaceutical composition comprising, as an active ingredient, a compound of any one of claims 1-3 or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers or diluents.
10. The use of the compound according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 9, in the preparation of a TRPV1 channel inhibitor.
11. The use of the compound or a pharmaceutically acceptable salt thereof according to any one of claims 1-3, or the pharmaceutical composition according to claim 9, in the preparation of a medicament for the prevention or treatment of diseases related to TRPV1 activity.
12. The application according to claim 11, wherein the TRPV1 activity-related diseases include: Painful conditions, chronic cough, asthma or airway hyperresponsiveness, or dermatitis-related itching.
13. The application according to claim 12, wherein the pain condition includes: Chronic pain, neuropathic pain, arthritic pain, rheumatic pain, fibromyalgia, back pain, cancer-related pain, facial neuralgia, headache, migraine, toothache, burn pain, postherpetic neuralgia, muscle pain, central or peripheral nerve compression pain, spinal cord or brain trauma pain, spinal cord or brain ischemic pain, neurodegenerative pain, pain after spinal cord or brain hemorrhage cerebrovascular accident, or pain after shock.
14. The application according to claim 13, wherein the neuropathic pain includes traumatic pain, diabetic pain, metabolic pain, infectious pain, toxic pain, cancer treatment-induced pain, or iatrogenic neuropathic pain.
15. The use of the compound according to any one of claims 1-3 or a pharmaceutically acceptable salt thereof, or the pharmaceutical composition according to claim 9, in the preparation of a medicament for the prevention or treatment of convulsions or epilepsy.
